Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18707536 | LIQUID FORMULATIONS OF AMYLIN ANALOGUES | May 2024 | December 2025 | Allow | 19 | 2 | 0 | No | No |
| 18632799 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | April 2024 | February 2025 | Allow | 10 | 0 | 1 | Yes | No |
| 18583562 | Peptide Synthesis in Aqueous Solution | February 2024 | September 2025 | Abandon | 19 | 2 | 1 | No | No |
| 18427270 | GLP-1 COMPOSITIONS AND USES THEREOF | January 2024 | September 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18538576 | COMPOSITIONS AND METHODS TO SUPPRESS TUMOR GROWTH IN BONE, PREVENT CACHECTIC MUSCLE LOSS, AND PRESERVE SKELETAL INTEGRITY | December 2023 | October 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18531607 | CYCLIC PEPTIDOMIMETIC FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | December 2023 | December 2024 | Allow | 13 | 1 | 0 | No | No |
| 18515712 | GLP-1 Analogues | November 2023 | August 2025 | Allow | 21 | 2 | 1 | Yes | No |
| 18383167 | SEMAGLUTIDE FOR USE IN MEDICINE | October 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18490341 | GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF | October 2023 | February 2026 | Abandon | 28 | 1 | 0 | No | No |
| 18479445 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | October 2023 | December 2024 | Abandon | 15 | 0 | 1 | No | No |
| 18474456 | POLYPEPTIDE INHIBITOR OF DE NOVO LIPOGENESIS IN CANCER CELLS | September 2023 | June 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18473846 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | September 2023 | June 2025 | Allow | 21 | 2 | 1 | No | No |
| 18459998 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | September 2023 | December 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18239441 | MOLECULAR PROBES AND METHODS OF USE | August 2023 | December 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18453807 | INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS | August 2023 | February 2025 | Allow | 18 | 1 | 1 | No | No |
| 18453299 | COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME | August 2023 | October 2025 | Allow | 26 | 4 | 1 | No | No |
| 18448781 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | August 2023 | September 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18363999 | DAPTOMYCIN FORMULATIONS | August 2023 | March 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18226405 | GLP-1 COMPOSITIONS AND USES THEREOF | July 2023 | February 2026 | Allow | 31 | 3 | 1 | No | No |
| 18345506 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF | June 2023 | September 2025 | Allow | 27 | 1 | 1 | No | No |
| 18341636 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | June 2023 | September 2025 | Allow | 27 | 3 | 0 | Yes | No |
| 18211787 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | June 2023 | November 2025 | Abandon | 29 | 3 | 0 | No | No |
| 18333388 | PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE | June 2023 | April 2024 | Allow | 10 | 1 | 0 | No | No |
| 18207268 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | June 2023 | April 2024 | Allow | 10 | 1 | 0 | No | No |
| 18321803 | TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION | May 2023 | April 2025 | Allow | 23 | 2 | 1 | No | No |
| 18321788 | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (BOS) | May 2023 | August 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18320512 | THERAPEUTIC PEPTIDES | May 2023 | August 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18309671 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | April 2023 | November 2023 | Allow | 7 | 0 | 0 | No | No |
| 18034670 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18296697 | Peptide Oligonucleotide Conjugates | April 2023 | October 2024 | Allow | 19 | 2 | 1 | No | No |
| 18189057 | AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS | March 2023 | February 2025 | Allow | 23 | 1 | 1 | No | No |
| 18184605 | SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | March 2023 | March 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18169158 | PROTEASOME INHIBITORS | February 2023 | January 2024 | Allow | 11 | 1 | 1 | No | No |
| 18167864 | PREVENTING BIOLOGICAL TISSUE ADHESION | February 2023 | May 2025 | Allow | 27 | 3 | 0 | Yes | Yes |
| 18164335 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | February 2023 | August 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18164340 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | February 2023 | August 2024 | Abandon | 19 | 2 | 1 | No | No |
| 18161773 | NOVEL PEPTOID POLYMERS AND METHODS OF USE | January 2023 | May 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18083651 | COMBINATION COMPRISING A GLUCOCORTICOID AND EDO-S101 | December 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 18066170 | IMMUNORHELIN COMPOUNDS FOR INTRACELLULAR INFECTIONS | December 2022 | April 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18009408 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | December 2022 | March 2026 | Allow | 39 | 1 | 0 | Yes | No |
| 18009230 | THERAPEUTICS FOR TREATMENT OF COVID-19 SYMPTOMS | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18000946 | CYCLIC PEPTIDE INHIBITORS OF PSD-95 AND USES THEREOF | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17999524 | MODULAR AND GENERALIZABLE BIOSENSOR PLATFORM BASED ON DE NOVO DESIGNED PROTEIN SWITCHES | November 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18052768 | C3B BINDING POLYPEPTIDE | November 2022 | September 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17978800 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | November 2022 | December 2025 | Allow | 37 | 3 | 1 | No | No |
| 17976942 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | October 2022 | May 2023 | Allow | 7 | 1 | 0 | No | No |
| 17917673 | COMPOSITIONS AND METHODS FOR TREATING COMPLICATIONS OF VIRAL INFECTIONS AND OTHER RESPIRATORY DISORDERS | October 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17938236 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | October 2022 | December 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17937788 | Long-Acting Adrenomedullin Derivative | October 2022 | August 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17914805 | USE OF PHYCOBILIPROTEIN (PBP) TO INHIBIT OR TREAT SARS-COV-2 INFECTION | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17935140 | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (BOS) | September 2022 | February 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 17933963 | Compositions and Methods for Selective Labeling of Secondary Amines | September 2022 | August 2024 | Allow | 23 | 1 | 1 | No | No |
| 17948279 | SEMAGLUTIDE FOR USE IN MEDICINE | September 2022 | December 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17912482 | MOLECULAR TRANSPORT SYSTEM TO THE CENTRAL NERVOUS SYSTEM | September 2022 | February 2026 | Allow | 41 | 2 | 1 | No | No |
| 17822174 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | August 2022 | March 2023 | Allow | 7 | 0 | 1 | Yes | No |
| 17819466 | Novel GLP-1 Analogues | August 2022 | August 2023 | Allow | 12 | 2 | 0 | No | No |
| 17817836 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF STAPLED PEPTIDES | August 2022 | May 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17881244 | Blood Plasma Fractions for Use in Muscle Regeneration | August 2022 | April 2024 | Allow | 20 | 4 | 0 | Yes | No |
| 17880023 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | August 2022 | February 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17816577 | NOVEL GLP-1 ANALOGUES | August 2022 | August 2023 | Allow | 13 | 2 | 0 | No | No |
| 17815371 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | July 2022 | July 2023 | Allow | 12 | 1 | 1 | No | No |
| 17873269 | GLYCOPEPTIDE ANTIBIOTIC COMBINATION THERAPY | July 2022 | September 2025 | Allow | 38 | 3 | 1 | Yes | No |
| 17862086 | PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS | July 2022 | January 2026 | Allow | 42 | 1 | 0 | Yes | No |
| 17854379 | PCSK9 ANTAGONIST COMPOUNDS | June 2022 | September 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17847750 | Prodrug Comprising a Drug Linker Conjugate | June 2022 | February 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17839390 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | June 2022 | August 2024 | Allow | 26 | 2 | 1 | No | No |
| 17836425 | ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ErbB4 BUT NOT AGAINST ErbB3 | June 2022 | February 2026 | Allow | 44 | 3 | 1 | Yes | No |
| 17834293 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | June 2022 | January 2023 | Allow | 7 | 0 | 0 | No | No |
| 17832868 | LYSOBACTIN FOR USE IN THE TREATMENT OF BOVINE MASTITIS | June 2022 | January 2024 | Abandon | 20 | 1 | 1 | No | No |
| 17832107 | CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF | June 2022 | July 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17804217 | SUSTAINED DELIVERY OF ANGIOPOETIN-LIKE 3 POLYPEPTIDES | May 2022 | January 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17664539 | PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE | May 2022 | March 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17745710 | CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES | May 2022 | July 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17738283 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | May 2022 | January 2025 | Allow | 33 | 3 | 1 | Yes | No |
| 17732285 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | April 2022 | September 2025 | Allow | 41 | 4 | 1 | Yes | No |
| 17726604 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | April 2022 | January 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17719095 | AQUEOUS SUSPENSIONS OF CYCLOSPORIN | April 2022 | August 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17658082 | CONJUGATE FOR TARGETING THERAPY | April 2022 | August 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17707497 | STABLE PHARMACEUTICAL COMPOSITION OF VASOPRESSIN | March 2022 | March 2023 | Allow | 11 | 1 | 0 | No | No |
| 17700860 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | March 2022 | September 2023 | Allow | 18 | 2 | 1 | Yes | No |
| 17694513 | HEPARIN-PEPTIDE BIOCONJUGATES AND USES THEREOF | March 2022 | June 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17692821 | SMALL MOLECULE SUPPRESSORS OF APOE GENE EXPRESSION AND CEREBRAL VASCULAR AMYLOID PATHOLOGY | March 2022 | August 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17690809 | CYCLIC PEPTIDOMIMETIC FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | March 2022 | September 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17681248 | PROLINE-LOCKED STAPLED PEPTIDES AND USES THEREOF | February 2022 | April 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17667002 | METHODS FOR ANTIBODY DRUG CONJUGATION, PURIFICATION, AND FORMULATION | February 2022 | July 2025 | Abandon | 41 | 4 | 1 | No | No |
| 17582787 | ANTIPLASMODIAL COMPOUNDS | January 2022 | July 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17624849 | SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES | January 2022 | January 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17555154 | IL-17A BINDING PEPTIDES AND MEDICAL USES THEREOF | December 2021 | March 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17551971 | METHODS OF MODIFYING PHOSPHORYLATED OR SULFATED TYROSINE RESIDUES OF POLYPEPTIDES | December 2021 | December 2022 | Abandon | 12 | 1 | 1 | Yes | No |
| 17618233 | NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF | December 2021 | December 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17616561 | NOVEL ANTIVIRAL THERAPIES | December 2021 | February 2026 | Abandon | 50 | 0 | 1 | No | No |
| 17595960 | NOVEL PEPTOID BLOCKING O-GlcNAcylated NF-kappaB c-Rel | November 2021 | May 2025 | Allow | 41 | 0 | 0 | Yes | No |
| 17532849 | OPTOGENETIC MODULATION BY MULTI-CHARACTERISTIC OPSINS FOR VISION RESTORATION AND OTHER APPLICATIONS THEREOF | November 2021 | August 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17530664 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | November 2021 | July 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17524985 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | November 2021 | August 2024 | Abandon | 33 | 6 | 0 | Yes | No |
| 17524230 | NOVEL DEPSIPEPTIDES AND USES THEREOF | November 2021 | September 2023 | Allow | 22 | 2 | 0 | No | No |
| 17524022 | TERLIPRESSIN COMPOSITIONS AND THEIR METHODS OF USE | November 2021 | July 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17519838 | USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION | November 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17519638 | PREVENTING BIOLOGICAL TISSUE ADHESION | November 2021 | August 2023 | Abandon | 21 | 2 | 0 | No | No |
| 17519109 | COLLAGEN SCAFFOLDS | November 2021 | May 2023 | Allow | 18 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KATAKAM, SUDHAKAR.
With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 45.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner KATAKAM, SUDHAKAR works in Art Unit 1658 and has examined 595 patent applications in our dataset. With an allowance rate of 81.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 27 months.
Examiner KATAKAM, SUDHAKAR's allowance rate of 81.0% places them in the 52% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by KATAKAM, SUDHAKAR receive 1.67 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KATAKAM, SUDHAKAR is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +21.7% benefit to allowance rate for applications examined by KATAKAM, SUDHAKAR. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 33.4% of applications are subsequently allowed. This success rate is in the 73% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 78.6% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 42.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 59.5% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 8.4% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.7% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.